FibroGen, Inc. (FGEN)
Largest Insider Buys in Sector
FGEN Stock Price History Chart
FGEN Stock Performance
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human …
Insider Activity of FibroGen, Inc.
Over the last 12 months, insiders at FibroGen, Inc. have bought $121,354 and sold $0 worth of FibroGen, Inc. stock.
On average, over the past 5 years, insiders at FibroGen, Inc. have bought $381,993 and sold $2.92M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Wettig Thane (CEO) — $95,470. Adib Deyaa (Chief Medical Officer) — $25,884.
The last purchase of 22,123 shares for transaction amount of $25,884 was made by Adib Deyaa (Chief Medical Officer) on 2024‑06‑12.
List of Insider Buy and Sell Transactions, FibroGen, Inc.
| 2024-06-12 | Chief Medical Officer | 22,123 0.023% | $1.17 | $25,884 | -65.95% | |||
| 2024-03-07 | CEO | 50,000 0.0545% | $1.91 | $95,470 | -43.70% | |||
| 2023-09-01 | Sale | director | 2,000 0.002% | $1.03 | $2,060 | -6.74% | ||
| 2023-08-04 | Sale | director | 2,000 0.002% | $1.91 | $3,820 | -42.15% | ||
| 2023-07-11 | Sale | director | 2,000 0.0021% | $2.69 | $5,380 | -58.24% | ||
| 2023-07-07 | Sale | Chief Executive Officer | 1,880 0.0021% | $2.80 | $5,264 | -57.78% | ||
| 2023-06-23 | Sale | Chief Commercial Officer | 791 0.0009% | $16.53 | $13,075 | -92.77% | ||
| 2023-06-14 | Sale | SVP, China Operations | 6,250 0.0068% | $16.79 | $104,925 | -92.86% | ||
| 2023-06-13 | Sale | SVP, China Operations | 6,250 0.0066% | $17.60 | $110,000 | -93.28% | ||
| 2023-06-09 | Sale | director | 7,889 0.0084% | $17.19 | $135,622 | -92.99% | ||
| 2023-06-09 | Sale | director | 8,520 0.0091% | $17.20 | $146,571 | -92.99% | ||
| 2023-06-09 | Sale | director | 3,944 0.0042% | $17.17 | $67,717 | -92.99% | ||
| 2023-06-09 | Sale | director | 4,733 0.0051% | $17.19 | $81,367 | -92.99% | ||
| 2023-06-08 | Sale | director | 7,000 0.0073% | $17.45 | $122,185 | -93.28% | ||
| 2023-06-08 | Sale | director | 8,520 0.0088% | $17.44 | $148,591 | -93.28% | ||
| 2023-06-07 | Sale | Chief Executive Officer | 8,897 0.0093% | $17.04 | $151,583 | -92.99% | ||
| 2023-06-07 | Sale | SVP, China Operations | 3,633 0.0038% | $17.04 | $61,894 | -92.99% | ||
| 2023-06-07 | Sale | EVP, Chief Medical Officer | 2,042 0.0021% | $17.04 | $34,792 | -92.99% | ||
| 2023-06-07 | Sale | Chief Commercial Officer | 1,758 0.0018% | $17.04 | $29,951 | -92.99% | ||
| 2023-06-07 | Sale | director | 7,100 0.0079% | $18.03 | $127,987 | -92.99% |
Insider Historical Profitability
| Wettig Thane | CEO | 470178 0.4666% | $0.58 | 2 | 7 | +7.99% |
| Adib Deyaa | Chief Medical Officer | 82123 0.0815% | $0.58 | 1 | 0 | |
| Conterno Enrique A | Chief Executive Officer | 374722 0.3719% | $0.58 | 2 | 7 | +14.48% |
| Lema Gerald | director | 3500 0.0035% | $0.58 | 1 | 0 | +19.61% |
Institutional Investor Ownership
| PRIMECAP Management Co | $33.89M | 14.5 | 14.42M | -0.35% | -$119,309.50 | 0.03 | |
| Armistice Capital Llc | $18.65M | 7.98 | 7.94M | -18.72% | -$4.3M | 0.06 | |
| BlackRock | $16.37M | 7.01 | 6.97M | -3.29% | -$557,847.69 | <0.0001 | |
| The Vanguard Group | $15.13M | 6.47 | 6.44M | -8.62% | -$1.43M | <0.0001 | |
| Acadian Asset Management | $5.88M | 2.52 | 2.5M | +1.42% | +$82,086.84 | 0.02 |